NTLA
Price
$7.41
Change
+$0.64 (+9.45%)
Updated
Apr 11 closing price
Capitalization
767.06M
19 days until earnings call
QLGN
Price
$3.00
Change
-$0.05 (-1.64%)
Updated
Apr 11 closing price
Capitalization
2.21M
Ad is loading...

NTLA vs QLGN

Header iconNTLA vs QLGN Comparison
Open Charts NTLA vs QLGNBanner chart's image
Intellia Therapeutics
Price$7.41
Change+$0.64 (+9.45%)
Volume$2.36M
Capitalization767.06M
Qualigen Therapeutics
Price$3.00
Change-$0.05 (-1.64%)
Volume$24.96K
Capitalization2.21M
NTLA vs QLGN Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. QLGN commentary
Apr 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and QLGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 13, 2025
Stock price -- (NTLA: $7.41 vs. QLGN: $3.00)
Brand notoriety: NTLA and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 65% vs. QLGN: 41%
Market capitalization -- NTLA: $767.06M vs. QLGN: $2.21M
NTLA [@Biotechnology] is valued at $767.06M. QLGN’s [@Biotechnology] market capitalization is $2.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while QLGN’s TA Score has 3 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 3 bearish.
  • QLGN’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than QLGN.

Price Growth

NTLA (@Biotechnology) experienced а +11.76% price change this week, while QLGN (@Biotechnology) price change was -4.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

QLGN is expected to report earnings on Mar 01, 2023.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($767M) has a higher market cap than QLGN($2.21M). QLGN YTD gains are higher at: -28.741 vs. NTLA (-36.449). QLGN has higher annual earnings (EBITDA): -6.73M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. QLGN (388K). QLGN has less debt than NTLA: QLGN (1.43M) vs NTLA (210M). NTLA has higher revenues than QLGN: NTLA (57.9M) vs QLGN (0).
NTLAQLGNNTLA / QLGN
Capitalization767M2.21M34,722%
EBITDA-523.98M-6.73M7,785%
Gain YTD-36.449-28.741127%
P/E RatioN/A0.00-
Revenue57.9M0-
Total Cash602M388K155,155%
Total Debt210M1.43M14,644%
FUNDAMENTALS RATINGS
NTLA vs QLGN: Fundamental Ratings
NTLA
QLGN
OUTLOOK RATING
1..100
5581
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
9465
P/E GROWTH RATING
1..100
10037
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is in the same range as QLGN (33) in the null industry. This means that NTLA’s stock grew similarly to QLGN’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as QLGN (100) in the null industry. This means that NTLA’s stock grew similarly to QLGN’s over the last 12 months.

NTLA's SMR Rating (91) in the Biotechnology industry is in the same range as QLGN (100) in the null industry. This means that NTLA’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's Price Growth Rating (65) in the null industry is in the same range as NTLA (94) in the Biotechnology industry. This means that QLGN’s stock grew similarly to NTLA’s over the last 12 months.

QLGN's P/E Growth Rating (37) in the null industry is somewhat better than the same rating for NTLA (100) in the Biotechnology industry. This means that QLGN’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAQLGN
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
79%
Bullish Trend 16 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PQDMX13.47N/A
N/A
PGIM Quant Solutions Intl Dev Mkts IdxR6
SDGCX73.34N/A
N/A
DWS Capital Growth C
PPQJX3.04N/A
N/A
Principal MidCap Growth III J
TRREX10.66N/A
N/A
T. Rowe Price Real Estate
BTMGX15.57N/A
N/A
iShares MSCI EAFE Intl Idx G

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+9.45%
VCYT - NTLA
69%
Closely correlated
+5.12%
CRSP - NTLA
66%
Loosely correlated
+14.71%
BEAM - NTLA
63%
Loosely correlated
+5.74%
RXRX - NTLA
59%
Loosely correlated
+27.72%
RCKT - NTLA
59%
Loosely correlated
+6.68%
More

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with VERU. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
-1.64%
VERU - QLGN
34%
Loosely correlated
+3.47%
PHIO - QLGN
32%
Poorly correlated
+5.45%
NTLA - QLGN
30%
Poorly correlated
+9.45%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MNOV - QLGN
28%
Poorly correlated
+8.66%
More